Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension

British Journal of Ophthalmology

Volumn 90, Issue 11, 2006, Pages 1336-1337

  Noecker, R ^a  

^a University of Pittsburgh School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; LATANOPROST; TRAVOPROST;

CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; EDITORIAL; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MEDICAL INFORMATION; MONOTHERAPY; PRIORITY JOURNAL;

AMIDES; CLOPROSTENOL; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; OCULAR HYPERTENSION; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 33750682654     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.098889     Document Type: Editorial

References (6)

1. Cantor LB, Hoop JS, Morgan L. IOP-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with gaucoma or ocular hypertension. Brt J Opthalmol 2006;90:1370-3.
2. Parrish RK, Palmberg P, Sheu WP, et al. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703.
3. Noecker R, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003;135:55-63.
4. Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001;18:110-21.
5. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-84.
6. Noecker RJ, Earl ML, Mundorf T, et al. Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension. Adv Ther 2003;20:121-8.